Pacira BioSciences, Inc. (FRA:82P)
Germany · Delayed Price · Currency is EUR | Market Cap | 777.58M -27.6% |
| Revenue (ttm) | 637.35M +4.6% |
| Net Income | 4.46M |
| EPS | 0.10 |
| Shares Out | n/a |
| PE Ratio | 174.49 |
| Forward PE | 7.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 18.90 |
| Previous Close | 19.40 |
| Day's Range | 18.80 - 18.90 |
| 52-Week Range | 15.40 - 23.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Pacira BioSciences
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos... [Read more]
News
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change" BRISBANE, Calif., June 1, 2026 /PRNewswire/ -- ...
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
First quarter 2026 revenue up 79.4% compared to the first quarter of 2025 First quarter 2026 gross profit increased 71.9% compared to the first quarter of 2025 First quarter same-store sales were up 7...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Glass Lewis recommends shareholders vote for Pacira director nominees
Pacira (PCRX) announced that leading independent proxy advisory firm Glass Lewis has recommended that Pacira stockholders vote “FOR” each of Pacira’s three director nominees and “AGAINST” all three of...
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees
BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain the...
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE DOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AN...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
Clarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE P...
Pacira study shows Exparel reduces opioid use and costs
Pacira (PCRX) BioSciences announced findings from a real-world study evaluating outcomes associated with the use of Exparel following outpatient total shoulder arthroplasty in Medicare Advantage patie...
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE NE...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 27, 2026, providing details for shareholder voting and corporate governance matters.
Pacira issues statement on DOMA’s ‘misleading’ statements
Pacira (PCRX) BioSciences issued the following statement with important facts stockholders should know regarding Pacira’s intellectual property strategy, and DOMA Perpetual Capital Management’s recent...
Pacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property Strategy
Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
Purchase price of approximately $8.2 million The acquisition represents a continued expansion of PharmaCorp's footprint in Ontario SASKATOON, Saskatchewan, May 25, 2026 (GLOBE NEWSWIRE) -- PHARMACORP ...
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), WHILE ALLO...
Doma Perpetual urges Pacira shareholders to vote for its board candidates
DOMA Perpetual Capital Management which, together with its affiliates, beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira (PCRX) BioSciences, announced that membe...
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change Intend to Work Collaboratively with Incum...
Pacira BioSciences Transcript: RBC Capital Markets Global Healthcare Conference 2026
Q1 2026 showed strong volume and revenue growth, with the gap expected to narrow as GPO discounting eases. Expansion of coverage and adoption of the NOPAIN Act are key growth drivers, supported by robust clinical evidence and a pipeline rich in late-stage data. International partnerships and disciplined capital allocation underpin long-term growth ambitions.
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
Pacira BioSciences Slides: Investor presentation
Pacira BioSciences has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Doma Perpetual urges Pacira shareholders to vote for its board candidates
DOMA Perpetual Capital Management, which, together with its affiliates, beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira (PCRX) BioSciences, has sent a letter t...
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA Contends This Conduct Constitutes a Failure of th...